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Prostate cancer (PCa) is the most common male cancer 
[1, 2]. PCa initially depends on androgen receptor (AR) 
signaling for growth and survival. Androgen deprivation 
therapy causes a temporary reduction in PCa tumor bur-
den, but the tumor eventually develops into castration-
resistant prostate cancer (CRPC) with the ability to grow 
again in the absence of androgens [3]. Mechanisms of 
CRPC progression include AR amplification and overex-
pression [4], AR gene rearrangement promoting synthesis 
of constitutively-active truncated AR splice variants (AR-
Vs) [4], and induction of intracrine androgen metabolic 
enzymes [3]. Current anti-androgen therapies including 
MDV3100 (Enzalutamide) and abiraterone have focused 
on the androgen-dependent activation of AR through its 
ligand-binding domain (LBD), but do not provide a con-
tinuing clinical benefit for patients with CRPC and pre-
sumably fail due to multiple mechanisms including the 
expression of AR-Vs lacking the LBD [5]. These AR-Vs 
signal in the absence of ligand and are therefore resistant 
to LBD-targeting AR antagonists or agents that repress 
androgen biosynthesis [6].
To identify compounds that block the transcrip-
tional activities of both ligand-dependent full-length 
AR (AR-FL) and AR-Vs, we used the MMTV-luciferase 
(MMTV-luc) reporter system that contains AR-binding 
elements [7] to screen approximately 100 compounds 
from a library of natural compounds from Traditional 
Chinese Medicine and identified a small-molecule com-
pound termed ailanthone, which is extracted from the 
whole seedlings of Ailanthus altissima (Simaroubaceae) 
that has antimalarial and antitumor activities [8]. In our 
work recently reported in the paper entitled “Ailanthone 
targets p23 to overcome MDV3100 resistance in castra-
tion-resistant prostate cancer” in Nature Communica-
tions [9], ailanthone not only blocked the ligand-induced 
activities of full-length AR but also inhibited AR-V 
which lacks the LBD at low concentrations (AR-FL half 
maximal inhibitory concentration [IC50]  =  69  nmol/L, 
95% confidence interval [CI]  =  53–89  nmol/L; AR1–651 
[a constructed AR splice variant] IC50  =  309  nmol/L, 
95% CI =  236–687  nmol/L in 22RV1 cells). Ailanthone 
decreased the androgen-dependent induction of endog-
enous AR downstream genes PSA, TMPRSS2, FKBP5, 
SLC45A3, and NDRG1 mRNA expression in LNCaP cells. 
To investigate whether ailanthone suppressed the func-
tioning of AR-V which lacks the LBD, we performed RNA 
sequencing after treating LNCaP cells with or without 
ailanthone in the absence or presence of AR1–651. Indeed, 
ailanthone strongly suppressed AR1–651-induced expres-
sion of some genes, such as PSA and TMPRSS2, support-
ing the potential therapeutic use of ailanthone in CRPC. 
Moreover, ailanthone reduced the expression of both the 
full-length AR and the AR-Vs in vitro and in vivo. Using 
the sulforhodamine B colorimetric (SRB) assay, we con-
firmed that ailanthone potently inhibited the growth of 
several PCa cell lines including LNCaP, c4–2b, 22RV1, 
and LAPC4. Interestingly, ailanthone more potently 
inhibited the growth of AR-positive PCa cells than either 
AR-negative tumor cell lines or normal prostate cell 
lines. Notably, not only intraperitoneal injection admin-
istration but also per os administration of ailanthone had 
excellent efficiency for blocking the growth and metasta-
sis of CRPC in LNCaP, 22RV1, and VCaP subcutaneous 
xenografts and 22RV1-luc orthotopic xenografts.
Our study also explored the mechanism of ailanthone-
induced AR degradation [9]. We found that ailanthone 
disrupted the interaction between AR and the chaper-
ones HSP90, HSP70, and HSP40, and consequently AR 
was ubiquitinated and degradated through the proteas-
ome-mediated pathway. When not bound to ligand, AR 
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resides in the cytosol bound to the foldosome, a complex 
of heat shock, chaperone, and co-chaperone proteins 
including HSP90, HSP70, HSP40, and p23. Ailanthone 
could bind to p23 protein which is very important for the 
stabilization of the HSP90-client complex, and ailanthone 
prevented the interaction of HSP90 with p23. Given that 
ailanthone was able to bind to p23 and knockdown of p23 
substantially prevented ailanthone-induced cell growth 
arrest, we propose that ailanthone induces AR degrada-
tion through binding to p23 and disrupting the HSP90-
client complex. Indeed, PCa cells that express AR showed 
greater sensitivity to ailanthone at lower concentration, 
suggesting the degradation of AR by ailanthone plays a 
major role in inhibiting the growth of AR-positive PCa 
cells at low concentrations of ailanthone. Therefore, we 
conclude that targeting p23 is the major mechanism of 
ailanthone and that ailanthone-induced AR degradation 
is at least a critical mechanism of ailanthone-dependent 
cell growth inhibition in PCa. However, how ailanthone 
regulates the molecular conformation of p23 and pre-
vents the interaction of p23 with HSP90 remains unde-
termined in our work. Clarifying the mechanism of 
ailanthone remains to be further investigated.
In pharmacokinetic studies, ailanthone exhibited good 
solubility in water and good bioavailability (>20%). We 
addressed some key safety issues of ailanthone, such as 
cytochromes P450 (CYPs) inhibition and hepatotoxicity. 
The current study showed that ailanthone had no obvi-
ous inhibitory effects on the main CYPs in humans and 
rats. In addition, ailanthone did not influence the expres-
sion of CYP enzymes and had no significant hepatotox-
icity after a 5-day administration in the present study. 
Therefore, ailanthone would have a low potential to cause 
possible toxicity and drug–drug interactions in which 
CYP enzymes are involved, suggesting a sufficient safety 
window for its putative use as a promising anticancer 
agent. Meanwhile, various physicochemical properties 
of ailanthone calculated on the ACD/I-Lab showed that 
the physiochemical parameters of the natural compound 
ailanthone met with “Lipinski’s Rule of Five” [10]. Our 
results suggest that ailanthone can be developed as a 
potential drug candidate with various drug formulations 
because of its ideal solubility and bioavailability.
In conclusion, we screened and characterized ailan-
thone, a novel compound with excellent drug-like char-
acteristics that is able to overcome MDV3100-resistance 
in PCa cell lines. Ailanthone was efficacious in suppress-
ing the growth and metastasis of CRPC via targeting p23. 
As a result, ailanthone can be considered a new poten-
tial drug candidate for PCa, and it is worthy of further 
research and investigation.
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